[A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung]. 1986

K Konno, and F Nagahama, and Y Nakai, and T Nakabayashi, and Y Hiraga, and K Takebe, and M Tamura, and K Oizumi, and M Sato, and T Ito

A phase II clinical trial of VP-16-213 was carried out in 71 patients with small cell and non-small cell carcinoma of the lung. Forty-eight evaluable cases consisted of 36 small cell carcinomas, 7 epidermoid carcinomas, 4 adenocarcinomas and one unclassified carcinoma. VP-16-213 was administered by drip infusion at dosages of 60-100mg/m2/day for 5-consecutive days at 3-4 week intervals. Twelve of 36 (33.3%) small cell carcinomas had partial responses, while no responses were obtained in non-small cell carcinomas. Median duration of responses was 46 days (range 31-133 days). The dose limiting toxicity was leukopenia. Median number of days to nadir was 14 days and median numbers of days for recovery was 11 days. Nausea (38%), vomiting (12%), anorexia (45%) and alopecia (74%) were major clinical toxicities although these were mild or reversible. We concluded that VP-16-213 was useful in the treatment of small cell lung cancer and the dose schedule used in this study was recommendable with small dose reduction for further trial of combination chemotherapy.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D011034 Podophyllotoxin A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives. Epipodophyllotoxin,CPH86,Condyline,Condylox,Podocon-25,Podofilm,Podofilox,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-Isomer,Wartec,Warticon
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females

Related Publications

K Konno, and F Nagahama, and Y Nakai, and T Nakabayashi, and Y Hiraga, and K Takebe, and M Tamura, and K Oizumi, and M Sato, and T Ito
February 1982, American journal of clinical oncology,
K Konno, and F Nagahama, and Y Nakai, and T Nakabayashi, and Y Hiraga, and K Takebe, and M Tamura, and K Oizumi, and M Sato, and T Ito
December 1987, Cancer,
K Konno, and F Nagahama, and Y Nakai, and T Nakabayashi, and Y Hiraga, and K Takebe, and M Tamura, and K Oizumi, and M Sato, and T Ito
October 1984, Onkologie,
K Konno, and F Nagahama, and Y Nakai, and T Nakabayashi, and Y Hiraga, and K Takebe, and M Tamura, and K Oizumi, and M Sato, and T Ito
December 1983, Onkologie,
K Konno, and F Nagahama, and Y Nakai, and T Nakabayashi, and Y Hiraga, and K Takebe, and M Tamura, and K Oizumi, and M Sato, and T Ito
October 1981, European journal of cancer & clinical oncology,
K Konno, and F Nagahama, and Y Nakai, and T Nakabayashi, and Y Hiraga, and K Takebe, and M Tamura, and K Oizumi, and M Sato, and T Ito
January 1981, Cancer treatment reports,
K Konno, and F Nagahama, and Y Nakai, and T Nakabayashi, and Y Hiraga, and K Takebe, and M Tamura, and K Oizumi, and M Sato, and T Ito
September 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
K Konno, and F Nagahama, and Y Nakai, and T Nakabayashi, and Y Hiraga, and K Takebe, and M Tamura, and K Oizumi, and M Sato, and T Ito
January 1981, Medical and pediatric oncology,
K Konno, and F Nagahama, and Y Nakai, and T Nakabayashi, and Y Hiraga, and K Takebe, and M Tamura, and K Oizumi, and M Sato, and T Ito
January 1977, Cancer treatment reports,
K Konno, and F Nagahama, and Y Nakai, and T Nakabayashi, and Y Hiraga, and K Takebe, and M Tamura, and K Oizumi, and M Sato, and T Ito
October 1985, Gynecologic oncology,
Copied contents to your clipboard!